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leukemia (c m l ), and the patient was initiated on 
therapy with imatinib. The patient tolerated therapy 
with minimal adverse effects, and within 3 months 
of therapy initiation, she had mounted a complete 
cytogenetic response by peripheral blood Bcr–Abl 
mutation screening.
The patient continued to demonstrate a durable 
remission on imatinib therapy. However, at a time 
corresponding to roughly 4 years of imatinib therapy, 
the patient was noted to have onset of cough and 
shortness of breath. Imaging of the chest by c t  re-
vealed multiple pulmonary nodules, and c t -guided 
biopsy of a representative lesion was consistent with 
clear-cell carcinoma of the kidney. After a discussion 
of potential therapeutic options, the patient was initi-
ated on therapy with bevacizumab while continuing 
treatment with imatinib.
Six months after initiation of the bevacizumab 
therapy, interval imaging data shows no significant 
change (Figure 1), and the patient has experienced no 
toxicities related to either therapeutic agent.
2.  DISCUSSION
2.1  Targeted Therapy for mRCC and Cml
Chronic myelogenous leukemia and metastatic renal 
cell carcinoma (mr c c ) represent two disorders whose 
therapies have been revolutionized by the advent of 
targeted agents. The natural history of c m l  has been 
drastically altered by the Bcr–Abl tyrosine kinase 
inhibitor (t k i ) imatinib. Use of imatinib has been vali-
dated with 5-year follow-up data from a study of 1106 
patients randomized to either imatinib or interferon 
alfa plus cytarabine. In that study, a complete cyto-
genetic response was obtained in 69% of patients by 
12 months and in 87% of patients by 60 months 1.
Although imatinib provides a durable remission, 
patients refractory to the drug also have therapeutic 
alternatives such as dasatinib or nilotinib. Dasatinib, 
a Bcr–Abl t k i that targets most imatinib-resistant 
BCR–ABL mutations, was shown to cause a complete 
hematologic response in 93% of patients assessed with 
chronic-phase c m l , and a major hematologic response in 
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1.  CASE PRESENTATION
Upon abdominal computed tomography (c t) imaging 
performed to rule out nephrolithiasis, a 57-year-old 
woman was incidentally found to have a 5-cm renal 
mass. The patient subsequently underwent a right-
sided nephrectomy, and pathology analysis of the 
surgical specimen revealed a 5-cm Fuhrman grade 2 
clear-cell-type renal cell carcinoma. Imaging by c t  
of the chest, abdomen, and pelvis at that time showed 
no evidence of distant disease, and the patient was 
followed clinically by her urologist.
Roughly 2 years later, the patient presented to 
her primary care practitioner with vague complaints 
of fatigue and lethargy. Initial workup included a 
complete blood count, remarkable for a pronounced 
leucocytosis (30,000 white cells/μL, normal differ-
ential). Subsequent bone marrow examination was 
consistent with a diagnosis of chronic myelogenous RCC AND CML: A TARGETED APPROACH
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70% of patients with accelerated-phase disease 2. A 
similar study to assess the activity of nilotinib also 
yielded data suggesting activity of this novel t k i in the 
setting of imatinib-resistant c m l  3.
Emerging data also suggest the utility of a targeted 
approach to the treatment of mr c c . Based on results of 
a meta-analysis assessing six prospective trials, inter-
feron alfa had previously been accepted as the standard 
treatment for mr c c. A total of 463 patients with mr c c  
had received therapy with interferon alfa, yielding 
a median time to progression of 4.7 months and a 
median overall survival (o s ) of 13.1 months 4. Those 
data led to the use of interferon alfa as a comparator 
in the phase iii trial of sunitinib, an oral t k i  targeting 
the vascular endothelial growth factor receptor (v e g f r ) 
and platelet-derived growth factor receptor (p d g f r ) 5. 
In 750 patients with previously untreated clear-cell 
mr c c, an improvement in progression free survival 
(p f s) was observed with sunitinib [10.9 months vs. 
5.1 months; hazard ratio (h r ): 0.42; p < 0.001], paral-
leled by improvements in quality of life 6.
A distinct targeted approach has been used for 
patients refractory to standard therapy. In a trial us-
ing the agent sorafenib (a t k i  with inhibitory activity 
against v e g f r , p d g f r , Flt-3, and c-Kit) or placebo in 
such patients, a benefit in time to progression was 
observed with sorafenib (5.5 months vs. 2.8 months; 
h r : 0.44; p < 0.01) 7. For poor-risk patients, the agent 
temsirolimus (an inhibitor of the mammalian target 
of rapamycin) has similarly led to an improvement in 
p f s; moreover, temsirolimus is the first of the targeted 
therapies for mr c c  to also improve o s  (7.3 months in 
patients receiving interferon alfa vs. 10.9 months in 
patients receiving temsirolimus alone; h r : 0.73; 
p = 0.008) 8.
Beyond small-molecule t k i s, monoclonal anti-
body (mAb) therapy for mr c c  has been evaluated 
in other recent studies. Bevacizumab, a mAb with 
specificity for v e g f r , was assessed in a phase iiitrial 
comparing the combination of bevacizumab and 
interferon alfa with interferon alfa and placebo. In 
649 randomized patients, a significant improvement 
in response rate was observed with the addition of 
bevacizumab (13% vs. 31%; p < 0.0001), with most of 
responses being characterized as partial. Median p f s 
was improved to 10.2 months from 5.4 months with 
the addition of bevacizumab (h r : 0.63; p < 0.0001), 
and at the time of this (interim) analysis, median o s  
in the bevacizumab-containing arm had not been 
reached 9.
2.2  Rationale for the Combination of Bevacizumab 
and Imatinib
The combination of bevacizumab and imatinib exclu-
sively has not been reported in the existing literature, 
but a recent trial tested these agents in combination 
with erlotinib. That study built on data from a random-
ized phase ii trial of first-line treatment of mr c c  with 
bevacizumab and erlotinib as compared with bevaci-
zumab and placebo. In 104 patients, the combination 
of bevacizumab and erlotinib did not significantly 
improve p f s (9.9 months vs. 8.5 months; h r : 0.86; 
p = 0.58). Interestingly, median o s  was not reached in 
the bevacizumab monotherapy group, but a median 
o s  of 20 months was noted with bevacizumab and 
erlotinib 10.
A separate phase i/ii trial that assessed bevaci-
zumab and erlotinib in combination with imatinib 
demonstrated a median p f s of 8.9 months and a me-
dian o s  of 20 months, thus mirroring the data obtained 
for single-agent therapy with bevacizumab. However, 
the addition of imatinib led to a marked increase in 
reported grades 3 and 4 toxicities, including diarrhea, 
f i g u r e  1 Computed tomography imaging demonstrates no appre-
ciable change in an index lesion (arrow) in the left lung (A) at the 
time of initiation of therapy with bevacizumab and imatinib, and 
(B) 6 months after initiation of therapy.
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rash, and fatigue 11. Thus, although the combination 
of erlotinib and bevacizumab is well tolerated, effi-
cacy data do not seem to support the addition of the 
erlotinib. Furthermore, addition of imatinib to this 
regimen appears to generate unacceptable toxicity.
The case described the present report represents a 
signal of activity for the combination of bevacizumab 
and imatinib exclusively. To date, no trials for this 
specific combination of agents are being conducted, 
although there are theoretical merits for the combi-
nation. Imatinib is an inhibitor of multiple tyrosine 
kinases, including Abl, Bcr–Abl, p d g f r , and c-Kit 1. 
Among these targets, p d g f r  is of particular relevance 
to r c c  and is a demonstrated target of sunitinib (to-
gether with v e g f r  and Flt-3) 5.
A retrospective analysis of 64 patients undergoing 
partial or radical nephrectomy for r c c  suggested that 
immunohistochemical staining for p d g f r  is a statisti-
cally significant prognostic factor for o s  on multivari-
ate analysis 12. Array studies of tissue suggest that r c c  
overproduces p d g f d , a recently discovered member of 
the p d g f  family. Transfection of p d g f d  in human r c c  
cell lines implanted in mice with severe combined 
immunodeficiency led to increased cellular prolifera-
tion and migration. Inhibition of p d g f r  β activity by 
imatinib led to a decline in tumour growth, suggesting 
a therapeutic role of imatinib in r c c  13.
Imatinib may target the kinase domain of cell 
surface receptors, but bevacizumab acts in a unique 
manner—through specific binding to v e g f . In vitro 
and in vivo assays have both demonstrated the role 
of v e g f  as a mitogen and angiogenesis inducer; be-
vacizumab has been shown in experimental models 
to reduce the growth rate of tumours, with decreased 
vessel density in bevacizumab-treated specimens 14. 
Other studies further suggest that bevacizumab may 
play a role in tumour vessel normalization, thereby 
alleviating tumour hypoxia and allowing for improved 
drug delivery to tumour tissue 15. The latter hypoth-
esis suggests a mechanism by which imatinib could 
potentially synergize with bevacizumab.
3.  CONCLUSIONS
Results from the phase i/ii trial combining bevaci-
zumab, erlotinib, and imatinib should not discourage 
further exploration of the combination of bevaci-
zumab and imatinib exclusively. The excessive toxic-
ity incurred with the addition of imatinib could be a 
result of overlapping downstream targets: although 
imatinib and erlotinib inactivate phosphorylation 
at distinct t k i s, the result is inhibition of common 
mitogenic pathways such as the p i3k–Akt signalling 
cascade 16,17. Given the exceptional tolerance and 
prolonged stable disease observed in the present case 
report, clinical studies of bevacizumab and imatinib 
should be pursued.
4.  RESEARCH SUPPORT AND DISCLAIMERS
No research funding was applied toward the effort 
reported here, and this research has not been previ-
ously presented.
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